Lamivudine therapy in kidney allograft recipients who are seropositive for hepatitis B surface antigen

Filik L., Karakayali H., Moray G., Dalgic A., Emiroglu R. , Ozdemir N., ...More

TRANSPLANTATION PROCEEDINGS, vol.38, no.2, pp.496-498, 2006 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 38 Issue: 2
  • Publication Date: 2006
  • Doi Number: 10.1016/j.transproceed.2005.12.047
  • Page Numbers: pp.496-498


Background. There are numerous recent reports on the use of lamivudine for hepatitis B virus (HBV) infection after renal transplantation. However, the optimal strategy (prophylactic, preemptive, or salvage approach) for starting lamivudine treatment in this patient group has not been determined. The aim of this study was to assess how the timing of lamivudine therapy affected the HBV serological status and the transaminase levels in renal allograft recipients with chronic HBV infection.